Endothelium-dependent vasoconstrictions in isolated vessel grafts : a novel mechanism of vasospasms ?

Background: YC-1 (3-(5'-hydroxymethyl-2'furyl)-1-benzyl-indazole) is an allosteric activator of soluble guanylyl cyclase (sGC) and a vasodilator. This study describes a paradox action of YC-1 in isolated vessels of coronary artery disease (CAD) patients which appears to trigger an endothelium-dependent vasoconstrictor pathway present in vessels with endothelial dysfunction. Methods: Effects of YC-1 on isolated vessel tensions were investigated in an organ bath. Vasoconstrictors released from vessels were quantified by ELISA. Results: YC-1 elicited long-lasting constrictions in saphenous veins and radial arteries from CAD patients, but not in human umbilical veins. Half-maximal effective dose was 1.0 μmol L. Constrictions were attenuated by nifedipine (L-type Ca channel blocker), bosentan (ETA/ETB inhibitor), BQ-788 (ETB inhibitor), and by denuding, but not by ODQ (sGC inhibitor), BQ-123 (ETA inhibitor), and phosphoramidon (endothelin converting enzyme inhibitor). Indometacin (cyclooxygenase-1/2 inhibitor) and SQ 29,548 (TP receptor antagonist) suppressed YC-1 induced constrictions, whereas 5,5-dimethyl-3-(3-fluorophenyl)-4-(4methylsulphonyl)phenyl-2(5H)-furanone (DFU, cyclooxygenase-2 inhibitor) had no effect. Saphenous vein rings released significantly more endothelin-1 in the presence of YC-1. Conclusions: YC-1 induced vasoconstrictions demonstrate the existence of an endothelium-dependent vasoconstrictor pathway in vessels of CAD patients which to date has only been described in animal models of hypertension. CAD patients with elevated endothelin-1 plasma levels are thus prone to endothelium-dependent vasoconstrictions which may also play a role in graft vasospasms.

[1]  T. Puehler,et al.  Effects of Shear Forces and Pressure on Blood Vessel Function and Metabolism in a Perfusion Bioreactor , 2010, Annals of Biomedical Engineering.

[2]  M. Frieden,et al.  Electrophysiological characterization of store-operated and agonist-induced Ca2+ entry pathways in endothelial cells , 2010, Pflügers Archiv - European Journal of Physiology.

[3]  A. Shaw,et al.  THEMED SECTION: ENDOTHELIUM IN PHARMACOLOGY RESEARCH PAPER Mechanisms of U46619-induced contraction of rat pulmonary arteries in the presence and absence of the endothelium , 2009 .

[4]  P. Vanhoutte,et al.  Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. , 2009, Pharmacology & therapeutics.

[5]  C. Schmid,et al.  Cardiovascular effects of modulators of soluble guanylyl cyclase activity. , 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry.

[6]  S. Yildirim,et al.  Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft. , 2007, Canadian journal of physiology and pharmacology.

[7]  G. Scheiner-Bobis,et al.  Signalling pathways involving sodium pump stimulate endothelin-1 secretion and nitric oxide production in endothelial cells. , 2006, Cellular and Molecular Biology.

[8]  V. Jacobs,et al.  Properties of the human umbilical vein as a living scaffold for a tissue-engineered vessel graft. , 2006, Tissue engineering.

[9]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[10]  P. Vanhoutte,et al.  Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). , 2006, American journal of physiology. Heart and circulatory physiology.

[11]  J. Zweier,et al.  Increased Expression of Cyclooxygenase-2 Mediates Enhanced Contraction to Endothelin ETA Receptor Stimulation in Endothelial Nitric Oxide Synthase Knockout Mice , 2006, Circulation research.

[12]  Sheng-Nan Wu,et al.  BAY 41‐2272, a potent activator of soluble guanylyl cyclase, stimulates calcium elevation and calcium‐activated potassium current in pituitary GH3 cells , 2005, Clinical and experimental pharmacology & physiology.

[13]  Jin Han,et al.  Endothelin-1 increases intracellular Ca(2+) in rabbit pulmonary artery smooth muscle cells through phospholipase C. , 2005, American journal of physiology. Heart and circulatory physiology.

[14]  David P. Wilson,et al.  Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. , 2005, The Biochemical journal.

[15]  S. Taddei,et al.  Endothelium‐dependent contractions in hypertension , 2005, British journal of pharmacology.

[16]  G. Scheiner-Bobis,et al.  Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. , 2004, European journal of biochemistry.

[17]  K. Channon,et al.  Comparative efficacies and durations of action of phenoxybenzamine, verapamil/nitroglycerin solution, and papaverine as topical antispasmodics for radial artery coronary bypass grafting. , 2003, The Journal of thoracic and cardiovascular surgery.

[18]  Chin‐Chung Wu,et al.  Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway. , 2003, Biochemical pharmacology.

[19]  C. Wanner,et al.  Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity , 1999, British journal of pharmacology.

[20]  F. Rosenfeldt,et al.  Pharmacology of coronary artery bypass grafts. , 1999, The Annals of thoracic surgery.

[21]  G. Schultz,et al.  YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. , 1998, Molecular pharmacology.

[22]  R. Paul,et al.  Role of extracellular Ca++ influx via L-type and non-L-type Ca++ channels in thromboxane A2 receptor-mediated contraction in rat aorta. , 1998, The Journal of pharmacology and experimental therapeutics.

[23]  R. Busse,et al.  Effect of YC‐1, an NO‐independent, superoxide‐sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators , 1997, British journal of pharmacology.

[24]  G. Schultz,et al.  Sensitizing soluble guanylyl cyclase to become a highly CO‐sensitive enzyme. , 1996, The EMBO journal.

[25]  J. Garthwaite,et al.  Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. , 1995, Molecular pharmacology.

[26]  S. Kuo,et al.  YC-1, a novel activator of platelet guanylate cyclase. , 1994, Blood.

[27]  M. Polokoff,et al.  Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. , 1994, Pharmacological reviews.

[28]  G. Gray,et al.  The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. , 1992, Biochemical and biophysical research communications.

[29]  K. Ohnaka,et al.  Presence of non‐selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation , 1991, FEBS letters.

[30]  S. Moncada,et al.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo , 1990, British journal of pharmacology.

[31]  D. Stewart,et al.  Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery. , 1990, European journal of pharmacology.

[32]  R. Ikegawa,et al.  Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. , 1990, Biochemical and biophysical research communications.

[33]  H. Nathan,et al.  Endothelium-Derived Relaxing and Contracting Factors , 2008 .

[34]  J. Garthwaite,et al.  Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition. , 2002, Molecular pharmacology.

[35]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[36]  L. Ghiadoni,et al.  Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. , 2000, Journal of cardiovascular pharmacology.

[37]  G. He,et al.  Arterial grafts for coronary artery bypass grafting: biological characteristics, functional classification, and clinical choice. , 1999, The Annals of thoracic surgery.

[38]  R. Gerzer,et al.  Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide , 1999, Journal of Molecular Medicine.

[39]  S. Taddei,et al.  Endothelium-dependent contractions to endothelin in the rat aorta are mediated by thromboxane A2. , 1993, Journal of cardiovascular pharmacology.